Supplementary Figure. Trends in Estimated Proportions of SARS-CoV-2 Reverse Transcription–Polymerase Chain Reaction Test Results With S-Gene Target Presence and Variant Proportions and Nowcast Projections FromGenomic Surveillance Classified by S-Gene Target Presence or S-Gene Target Failure — United States, September 27, 2023–January 20, 2024

Details

• Alternative Title:
  Early Estimates of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributableto Co-Circulating Omicron Variants Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, September 2023–January 2024: Supplementary Figure. Trends in Estimated Proportions of SARS-CoV-2 Reverse Transcription–Polymerase Chain Reaction Test Results With S-Gene Target Presence and Variant Proportions and Nowcast Projections FromGenomic Surveillance Classified by S-Gene Target Presence or S-Gene Target Failure — United States, September 27, 2023–January 20, 2024
• Corporate Authors:
  Centers for Disease Control and Prevention (U.S.)
• Source:
  MMWR: Morbidity and Mortality Weekly Report 2024; v. 73, no. 4
• Series:
  Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
• ISSN:
  0149-2195 (print) ; 1545-861X (digital)
• Document Type:
  Journal Article
• Place as Subject:
  United States
• Pages in Document:
  1 pdf page
• Volume:
  73
• Issue:
  4
• Collection(s):
  Morbidity and Mortality Weekly Report (MMWR)
• Main Document Checksum:
  urn:sha-512:0155fa3dd6df566ec761aae7676268f59f7eb6100ce296023f5347cf5c74dea298fd358a1cfeba96ce5e54c652994d459c4c0919fe3221816d6f0c284c0135ff
• Download URL:
  https://stacks.cdc.gov/view/cdc/145936/cdc_145936_DS1.pdf
• File Type:
  [PDF - 278.94 KB ]